Telcon Rf Pharmaceutical

Telcon RF Pharm was founded in 1999 and operates two core businesses: manufacturing wireless telecom connectors and cable assemblies, and producing finished pharmaceutical products.

The company holds four subsidiaries including its Vietnamese unit TELCON VINA, with the RF segment developing and producing wireless communication parts and telecom system products.

The pharma and bio segment manufactures various drug formulations at a KGMP-certified facility, while pursuing 5G-based FTTA solution development and expansion into Southeast Asian markets.

Pharma segment sales have been driven by steady demand growth for its gastrointestinal protectant product line, branded Algicel liquid (sodium alginate), and the company has stated it expects the pharma segment's revenue to expand to over KRW 35bn as market share for its flagship product strengthens.

The RF segment anticipates rising demand from 5G and optical solution market growth, but has faced operating pressure from a downturn in the telecom parts market, prompting efforts to diversify customers and develop higher-margin products.

Separately, Telcon RF Pharm has built up its position as the largest shareholder of oncology drug developer Abion over several years, and drew market attention when Abion announced a licensing deal reportedly worth about KRW 1.8 trillion for its solid tumor antibody candidate ABN501.

This equity holding structure adds a layer of asset value and earnings volatility distinct from the core RF and pharma manufacturing business. In sum, the company runs a bifurcated portfolio combining stable-revenue manufacturing (RF plus pharma) with a higher-growth, higher-risk biotech equity investment.

Annual results show pronounced volatility.

After a large loss in 2022 -- revenue of KRW 27.83bn, an operating loss of KRW 4.06bn (operating margin -14.6%), and a net loss attributable to owners of KRW 42.08bn -- 2023 saw revenue rise to KRW 36.31bn with operating profit turning positive at KRW 0.97bn (margin 2.7%) and owners' net income swinging to a KRW 13.91bn profit.

However, in 2024 revenue grew only modestly to KRW 37.87bn while operating income slipped back into a loss of KRW 0.07bn, and the owners' net loss widened to KRW 26.32bn.

In 2025, revenue increased to KRW 43.16bn and operating income turned positive again at KRW 0.72bn (margin 1.7%), yet the owners' net loss remained at KRW 11.46bn, underscoring a persistent gap between operating and bottom-line results.

On a quarterly basis, the swing between Q3 2025 (revenue KRW 9.82bn, operating loss KRW 0.09bn, net loss KRW 4.88bn) and Q4 2025 (revenue KRW 13.32bn, operating profit KRW 2.63bn, net profit KRW 9.85bn) stands out, and the sharp Q4 net profit jump may reflect equity-method gains or one-off items.

In Q1 2026, revenue fell to KRW 9.70bn with the operating loss widening to KRW 1.43bn and the net loss expanding to KRW 11.47bn, while Q2 2026 revenue surged to KRW 28.94bn yet an operating loss of KRW 0.81bn and net loss of KRW 10.98bn continued, showing that the revenue jump did not translate into an immediate earnings improvement.

Over the trailing four quarters (Q3 2025 through Q2 2026), the cumulative net loss attributable to owners totaled KRW 17.48bn, indicating the loss-making trend has persisted on an annualized basis as well.

On cash flow, operating cash flow was positive at KRW 1.67bn in 2025, similar to KRW 1.22bn in 2024, an improvement versus the negative flows of KRW -2.09bn in 2022 and KRW -1.13bn in 2023.

The two industries the company operates in follow different cycles.

The RF telecom components industry is closely tied to 5G infrastructure investment; industry forecasts point to gradual demand growth for related parts as 5G progressively replaces prior-generation technology, while a recent downturn in the telecom parts market itself has weighed on results.

As a result, the RF segment is diversifying its customer base and shifting toward higher value-added products such as opto-electric hybrid connectors and optical cable assemblies, alongside FTTA solutions for 5G base stations and expansion into Southeast Asian markets.

The pharma and bio segment, by contrast, shows relatively stable growth supported by demand for KGMP-based contract manufacturing, with gradual market share gains in commodity drug categories such as gastrointestinal protectants.

Within the KOSDAQ pharma and bio sector, Telcon RF Pharm is better characterized as a hybrid operator combining contract manufacturing with equity investment in biotech (such as Abion) rather than a company with its own proprietary drug pipeline.

Competitively, it is smaller in scale than pure-play CMO specialists or large generic drugmakers, but its separate RF parts revenue stream is a differentiating feature.

Both businesses remain exposed to their respective cyclical swings, creating a structural pattern in which weakness in one segment can offset improvement in the other.

The company has stated that it expects pharma segment revenue to expand to over KRW 35bn as market share for its flagship products strengthens, and it is investing in production and logistics infrastructure accordingly.

In April 2026, it decided on a third-party allotment capital raise (3 million common shares, KRW 3bn) to its largest shareholder Newon, with proceeds designated for facility investment -- specifically factory and warehouse expansion -- planned from mid-April through end-June 2026.

Separately, balance-sheet measures were also taken: in May 2026 the company decided on a 10-for-1 capital reduction of common shares to offset accumulated deficit, which halted trading from June 4 until the day before the new share listing.

The RF segment is pursuing customer diversification and higher-margin product development in response to the telecom parts market downturn, while seeking a potential recovery tied to 5G and optical solution demand growth.

Its equity stake in Abion, whose pipeline includes oncology candidates ABN401 (vabametkib) and ABN501 (a claudin-3 targeted candidate), has reportedly been the subject of licensing-out efforts and a sale process via third-party share allotment, and the progress of this process could directly affect the value of Telcon's holding.

Given that Q2 2026 revenue rose sharply from the prior quarter yet the net loss persisted, whether revenue expansion translates into actual earnings improvement remains a key point to monitor going forward.